Halozyme Therapeutics Inc. Common Stock (HALO)
Fast GrowerFairStock Score: 51/100 — MIXED
Key Financials
| Current Price | $67.12 |
| Market Cap | $8.1B |
| P/E Ratio | 23.55 |
| ROE | 99.4% |
| Dividend Yield | —% |
| Sector | Healthcare |
Strengths
- Generates $185 million in annual free cash flow (2.3% yield on market cap)
- High return on equity of 153.6% demonstrating efficient capital deployment
- Revenue growth of 51.6% demonstrates strong top-line momentum
Concerns
- Trades significantly above Graham Number ($5) with negative 1299% margin of safety—limited downside protection
- High leverage at 44.60x debt-to-equity increases financial risk and interest expense burden
- Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
AI Analysis
Halozyme Therapeutics Inc. Common Stock is a small-cap healthcare company valued at $8.1 billion. Revenue stands at $1.4 billion, though the company is currently unprofitable. From a quality standpoint, Halozyme shows Altman Z-Score of 2.8 in the grey zone and extraordinary 154% return on equity. On valuation, the stock is trading at a premium 26.0x earnings, with trades far above its Graham Number ($5) with no margin of safety. Growth dynamics show revenue growing at 51.6% and profit growth of -203.3%. Our composite FairStock Score of 51/100 reflects mixed fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.
Bull Case
Halozyme's 52% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $185 million in annual free cash flow (2.3% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.
Bear Case
Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer